Your cells need it for energy, DNA repair, and sirtuin activation. By middle age you have half as much as you did at 20. Here's what that means and what injectable NAD+ actually does.
Research context only. This page is for educational purposes based on published research. Not medical advice.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It's not a peptide — it's a small molecule essential to how your cells produce energy, repair DNA, and regulate aging-related proteins called sirtuins. Without adequate NAD+, cellular metabolism, repair, and resilience all degrade.
Here's the problem: NAD+ levels decline significantly with age. By middle age, most people have roughly half the NAD+ they had in their 20s. This decline is now understood to be a driver — not just a symptom — of age-related metabolic dysfunction, cognitive decline, and reduced cellular repair capacity.
Why it matters: NAD+ isn't a drug. It's something your body already makes and absolutely requires. The research question isn't whether NAD+ is important — it's whether supplementing declining levels in aging individuals can restore youthful cellular function. That's what the current wave of clinical research is testing.
Injectable NAD+ (SubQ or IV) is researched as a more direct delivery method than oral precursors like NMN or NR, which must be converted by the body before becoming NAD+. The injectable approach bypasses the conversion step and delivers the coenzyme directly into circulation.
NAD+ is a critical electron carrier in the mitochondrial electron transport chain. It accepts electrons from metabolic reactions and donates them to produce ATP — the cell's energy currency. Low NAD+ means reduced mitochondrial efficiency and cellular energy output.
PARP1 and other PARP enzymes consume NAD+ to repair damaged DNA. As DNA damage accumulates with age, PARP activity increases, depleting NAD+ further — creating a cycle that accelerates aging. Maintaining NAD+ supports the repair system's ability to keep up.
Sirtuins (SIRT1–7) are longevity-associated proteins that regulate gene expression, metabolism, and stress resistance. They require NAD+ as a cofactor to function. Low NAD+ = underactive sirtuins = accelerated aging hallmarks.
CD38 is an enzyme that consumes NAD+ during inflammatory responses. Chronic inflammation — increasingly common with age — depletes NAD+ continuously. This is one reason NAD+ supplementation may have both metabolic and anti-inflammatory effects.
The sirtuin connection: The same sirtuins activated by NAD+ are also activated by caloric restriction — the most reproducible life-extension intervention in animal models. NAD+ supplementation may partially mimic the metabolic effects of caloric restriction without the restriction itself. This is the core hypothesis behind the longevity research.
NAD+ research has accelerated dramatically since David Sinclair's lab at Harvard published foundational work connecting NAD+ decline to aging hallmarks. Animal studies consistently show life extension and metabolic improvements with NAD+ repletion. Human clinical trials are now underway at major institutions including Harvard, Washington University, and the Mayo Clinic.
Early human data shows improvements in muscle function, metabolic markers, and inflammatory markers with NAD+ supplementation. The evidence for injectable NAD+ specifically is strong for rapid bioavailability — it achieves peak blood levels faster than oral precursors and doesn't rely on enzymatic conversion.
The flush warning: IV NAD+ administered too quickly causes a well-known and unpleasant flush — racing heart, chest tightness, nausea, and a hot sensation. This is not dangerous but is very uncomfortable. SubQ injection avoids the rapid delivery that triggers this response. If IV is used, slow drip administration (over 2–3 hours) is standard.
NAD+ has an excellent safety profile overall — it's a natural cellular metabolite. The primary risk is the flush reaction from rapid IV administration, which is entirely a delivery method issue, not a compound toxicity issue.
NMN and NR are NAD+ precursors — they need to be converted to NAD+ by enzymes in the body. Injectable NAD+ delivers the final molecule directly. Whether precursor conversion is efficient enough to match injectable bioavailability is an active research question. For rapid repletion, injectable bypasses the conversion step entirely.
NAD+ repletion appears to restore some age-related metabolic decline in animal models and early human data. 'Reverses aging' is a significant overstatement. A more accurate framing: it may slow or partially compensate for age-related metabolic deterioration. The longevity research is promising but not conclusive in humans yet.
NAD+ is continuously consumed by cellular processes. A loading protocol followed by maintenance dosing is standard because levels will decline again without ongoing supplementation. It's a maintenance strategy, not a one-time fix.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator